pyrroles has been researched along with Paraganglioma, Gangliocytic in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aschelter, AM; Capriotti, G; Cerquetti, L; Lardo, P; Marchetti, P; Matarazzo, I; Nardone, MR; Petrangeli, E; Schiavi, F; Stigliano, A; Toscano, V | 1 |
| Bourcier, ME; Vinik, AI | 1 |
| Asa, SL; Cassol, CA; Ezzat, S; Guo, M; Liu, W; Winer, D | 1 |
| Bobrzyk, M; Chronowska, J; Kukla, U; Madej, P; Okopień, B; Łabuzek, K | 1 |
| Asa, SL; Broom, R; Evans, A; Ezzat, S; Freeman, M; Joshua, AM; Knox, JJ | 1 |
| Baldridge, LA; Cheng, L; Cummings, OW; Hahn, NM; Reckova, M; Sweeney, CJ | 1 |
| Al Ghuzlan, A; Anderson, P; Ayala-Ramirez, M; Baudin, E; Cabanillas, ME; Caramella, C; Chougnet, CN; Deandreis, D; Habra, MA; Jimenez, C; Leboulleux, S; Palmer, JL; Waguespack, SG | 1 |
7 other study(ies) available for pyrroles and Paraganglioma, Gangliocytic
| Article | Year |
|---|---|
Treatment responses to antiangiogenetic therapy and chemotherapy in nonsecreting paraganglioma (PGL4) of urinary bladder with SDHB mutation: A case report.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Indoles; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Paraganglioma; Pyrroles; Succinate Dehydrogenase; Sunitinib; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms | 2018 |
Sunitinib for the treatment of metastatic paraganglioma and vasoactive intestinal polypeptide-producing tumor (VIPoma).
Topics: Abdominal Neoplasms; Aged; Antineoplastic Agents; Biomarkers, Tumor; Child; Drug Administration Schedule; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Pancreatic Neoplasms; Paraganglioma; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Time Factors; Treatment Outcome; Vipoma | 2013 |
Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas.
Topics: Adrenal Gland Neoplasms; Adult; Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Design; Female; Humans; Immunohistochemistry; Indoles; Male; Mice; Middle Aged; Molecular Targeted Therapy; Mutation; Paraganglioma; Pheochromocytoma; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptor, Fibroblast Growth Factor, Type 4; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Succinate Dehydrogenase; Sunitinib; Tissue Array Analysis | 2014 |
[Antiangiogenic therapy of malignant pheochromocytoma and paraganglioma with the view to the recent scientific developments].
Topics: Adrenal Gland Neoplasms; Angiogenesis Inhibitors; Benzamides; Humans; Imatinib Mesylate; Indoles; Neovascularization, Pathologic; Paraganglioma; Pheochromocytoma; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib; Thalidomide | 2015 |
Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Adult; Antineoplastic Agents; Humans; Indoles; Male; Middle Aged; Mutation; Paraganglioma; Pheochromocytoma; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2009 |
Patient with malignant paraganglioma responding to the multikinase inhibitor sunitinib malate.
Topics: Adult; Antineoplastic Agents; Female; Humans; Indoles; Paraganglioma; Pyrroles; Sunitinib | 2009 |
Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas.
Topics: Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Indoles; Male; Middle Aged; Paraganglioma; Pheochromocytoma; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2012 |